A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
- Conditions
- Breast Cancer
- Interventions
- Registration Number
- NCT04873362
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes.
As of June 4, 2024, this study is no longer accepting any newly screened participants.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 1188
- Histologically confirmed invasive breast carcinoma
- Centrally-confirmed human epidermal growth factor receptor 2 (HER2)-positive invasive breast cancer
- Centrally confirmed PD-L1 and hormone receptor status
- Clinical stage at disease presentation (prior to neoadjuvant therapy): cT4/anyN/M0, any cT/N2-3/M0, or cT1-3/N0-1/M0 (participants with cT1mi/T1a/T1b/N0 are not eligible)
- Completion of pre-operative systemic chemotherapy including at least 9 weeks of taxane and 9 weeks of trastuzumab (anthracycline and/or additional HER2-targeted agents are permitted)
- <=12 weeks between primary surgery and randomization
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
- Screening left ventricular ejection fraction (LVEF) >= 50% and no decrease in LVEF by >15% from the pre-chemotherapy LVEF. If no pre-chemotherapy LVEF, screening LVEF >= 55%
- Life expectancy >= 6 months
- Adequate hematologic and end organ function
- Stage IV breast cancer
- An overall response of disease progression according to the investigator at the conclusion of preoperative systemic therapy
- Prior treatment with T-DM1, or atezolizumab, or other immune checkpoint inhibitors
- History of exposure to various cumulative doses of anthracyclines
- History of other malignancy within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or ductal carcinoma in situ (DCIS)
- Current grade >=2 peripheral neuropathy
- History of idiopathic pulmonary fibrosis, organizing pneumonia, or pneumonitis
- History of or active autoimmune disease or immune deficiency
- Treatment with immunostimulatory or immunosuppressive agents
- Cardiopulmonary dysfunction
- Any known active liver disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm A: Placebo + Trastuzumab Emtansine Placebo Participants will receive an intravenous (IV) infusion of placebo prior to the IV infusion of trastuzumab emtansine on Day 1 of each 21-day cycle for a total of 14 cycles. Arm A: Placebo + Trastuzumab Emtansine Trastuzumab Emtansine Participants will receive an intravenous (IV) infusion of placebo prior to the IV infusion of trastuzumab emtansine on Day 1 of each 21-day cycle for a total of 14 cycles. Arm A: Placebo + Trastuzumab Emtansine Trastuzumab Participants will receive an intravenous (IV) infusion of placebo prior to the IV infusion of trastuzumab emtansine on Day 1 of each 21-day cycle for a total of 14 cycles. Arm B: Atezolizumab + Trastuzumab Emtansine Atezolizumab Participants will receive an IV infusion of atezolizumab prior to the IV infusion of trastuzumab emtansine on Day 1 of each 21-day cycle for a total of 14 cycles. Arm B: Atezolizumab + Trastuzumab Emtansine Trastuzumab Emtansine Participants will receive an IV infusion of atezolizumab prior to the IV infusion of trastuzumab emtansine on Day 1 of each 21-day cycle for a total of 14 cycles. Arm B: Atezolizumab + Trastuzumab Emtansine Trastuzumab Participants will receive an IV infusion of atezolizumab prior to the IV infusion of trastuzumab emtansine on Day 1 of each 21-day cycle for a total of 14 cycles.
- Primary Outcome Measures
Name Time Method Invasive Disease-free Survival (IDFS) in the Full Analysis Set (FAS) From baseline until the first occurrence of iDFS event or death, through primary analysis data cut off (approximately 7 years) IDFS event is defined as the time from randomization to the first occurrence of the following events: ipsilateral invasive breast tumor recurrence, ipsilateral local-regional invasive breast cancer recurrence, contralateral invasive breast cancer, distant recurrence, death from any cause.
- Secondary Outcome Measures
Name Time Method Cmax for Total Trastuzumab Day 1 of Cycles 1 and 4 pre-infusion, Day 1 of Cycles 1 and 4 after 30 minutes post-infusion, (cycle=21 days) and at study treatment completion/discontinuation visit (approximately 11 months after Cycle 1 Day 1) Percentage of Participants with Anti-drug Antibodies (ADAs) to Atezolizumab Day 1 of Cycles 1 and 4 pre-infusion, Day 1 of Cycles 1 and 4 after 30 minutes post-infusion, Day 1 of Cycles 2, 3 and 8 (cycle=21 days) and at study treatment completion/discontinuation visit (approximately 11 months after Cycle 1 Day 1) Distant Recurrence-free Interval (DRFI) From baseline until distant disease recurrence, through the end of study (approximately 10 years from LPI) Overall Survival (OS) From baseline to death from any cause through the end of study (approximately 10 years from LPI) Mean Absolute Scores in GHS/QoL, Physical, Role, and Cognitive Function, as Assessed Using the EORTC QLQ-C30 From baseline until 2 years after study treatment completion/discontinuation visit (approximately 3 years) The European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire (EORTC QLQ-C30) is a self-reported measure. Functioning and symptoms items are scored on a 4-point scale: 1=Not at all, 2=A little, 3=Quite a bit, 4=Very much. GHS and QoL items are scored on a 7-point scale: 1=Very poor, 2, 3, 4, 5, 6, 7=Excellent. Scores will be transformed to a range of 0 to 100, with higher scores (i.e. closer to 100) reflecting better functioning, better GHS/QoL, and worse symptoms.
IDFS Including Second Primary Non-breast Invasive Cancer From baseline until the first occurrence of iDFS event or death, through the end of study (approximately 10 years from last participant in [LPI]) IDFS in the PD-L1-positive and the PD-L1-negative Population From baseline until the first occurrence of iDFS event or death, through the end of study (approximately 10 years from LPI) Defined as all randomized participants from the ITT population with a centrally assessed PD-L1-positive \[i.e., PD-L1 status of IC1/2/3\] or PD-L1-negative status \[i.e.,PD-L1 status of IC0\] at randomization as per corresponding stratification factors recorded in the interactive web-based response system (IWRS).
Disease-free Survival (DFS) From baseline until the first occurrence of DFS event or death, through the end of study (approximately 10 years from LPI) Mean Change From Baseline Scores in GHS/QoL, Physical, Role, and Cognitive Function, as Assessed Using the EORTC QLQ-C30 From baseline until 2 years after study treatment completion/discontinuation visit (approximately 3 years) The European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire (EORTC QLQ-C30) is a self-reported measure. Functioning and symptoms items are scored on a 4-point scale: 1=Not at all, 2=A little, 3=Quite a bit, 4=Very much. GHS and QoL items are scored on a 7-point scale: 1=Very poor, 2, 3, 4, 5, 6, 7=Excellent. Scores will be transformed to a range of 0 to 100, with higher scores (i.e. closer to 100) reflecting better functioning, better GHS/QoL, and worse symptoms.
Number of Participants with Clinically Meaningful Deterioration in Global Health Status/Quality of Life (GHS/QoL) Physical, Role, and Cognitive Function From baseline until 2 years after study treatment completion/discontinuation visit (approximately 3 years) Clinically Meaningful Deterioration will be Measured by Scales of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer (EORTC QLQ C30)
Percentage of Participants with Adverse Events (AEs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0) From baseline up to 10 years Maximum Serum Concentrations (Cmax) for Atezolizumab Day 1 of Cycles 1 and 4 pre-infusion, Day 1 of Cycles 1 and 4 after 30 minutes post-infusion, Day 1 of Cycles 2, 3 and 8 pre-infusion (cycle=21 days) and at study treatment completion/discontinuation visit (approximately 11 months after Cycle 1 Day 1) Cmax for Trastuzumab Emtansine Day 1 of Cycles 1 and 4 pre-infusion, Day 1 of Cycles 1 and 4 after 30 minutes post-infusion, (cycle=21 days) and at study treatment completion/discontinuation visit (approximately 11 months after Cycle 1 Day 1) Cmax for DM1 Day 1 of Cycles 1 and 4 pre-infusion, Day 1 of Cycles 1 and 4 after 30 minutes post-infusion, (cycle=21 days) and at study treatment completion/discontinuation visit (approximately 11 months after Cycle 1 Day 1) DM1 = a thiol-containing maytansinoid anti-microtubule agent; N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine
Minimum Serum Concentrations (Cmin) for Atezolizumab Day 1 of Cycles 1 and 4 pre-infusion, Day 1 of Cycles 1 and 4 after 30 minutes post-infusion, Day 1 of Cycles 2, 3 and 8 (cycle=21 days) and at study treatment completion/discontinuation visit (approximately 11 months after Cycle 1 Day 1) Percentage of Participants with ADAs to Trastuzumab Emtansine Day 1 of Cycles 1 and 4 pre-infusion, Day 1 of Cycles 1 and 4 after 30 minutes post-infusion, (cycle=21 days) and at study treatment completion/discontinuation visit (approximately 11 months after Cycle 1 Day 1)
Trial Locations
- Locations (242)
The West Clinic
🇺🇸Germantown, Tennessee, United States
Royal North Shore Hospital
🇦🇺St Leonards, New South Wales, Australia
Princess Alexandra Hospital
🇦🇺Woolloongabba, Queensland, Australia
Tiroler Landeskrankenanstalten Ges.M.B.H.
🇦🇹Innsbruck, Austria
Ordensklinikum Linz Barmherzige Schwestern
🇦🇹Linz, Austria
Lkh Salzburg - Univ. Klinikum Salzburg
🇦🇹Salzburg, Austria
Hospital Araujo Jorge
🇧🇷Goiania, Goiás, Brazil
Núcleo de Pesquisa São Camilo
🇧🇷Sao Paulo, São Paulo, Brazil
COC Plovdiv
🇧🇬Plovdiv, Bulgaria
Medical Center "Nadezhda Clinical" EOOD
🇧🇬Sofia, Bulgaria
Guangdong Provincial People's Hospital
🇨🇳Guangzhou City, China
Masaryk?v onkologický ústav
🇨🇿Brno, Czechia
Fakultni Nemocnice Hradec Kralove
🇨🇿Hradec Kralove, Czechia
Nemocnice AGEL Novy Jicin a.s.
🇨🇿Novy Jicin, Czechia
Fakultni nemocnice Olomouc
🇨🇿Olomouc, Czechia
Fakultni Poliklinika Vseobecne Fakultni Niemocnice
🇨🇿Praha 2, Czechia
Fakultni Thomayerova nemocnice
🇨🇿Praha 4 - Krc, Czechia
Vejle Sygehus
🇩🇰Vejle, Denmark
Centre Francois Baclesse
🇫🇷Caen, France
Groupe Hospitalier Public Du Sud De L'Oise GHPSO
🇫🇷Creil Cedex 1, France
Centre Hospitalier Uni Ire Caremeau
🇫🇷Nimes, France
Institut Curie
🇫🇷Paris, France
HOPITAL RENE HUGUENIN, Institut Curie
🇫🇷Saint-Cloud, France
Klinikum Augsburg
🇩🇪Augsburg, Germany
Hochwaldkrankenhaus
🇩🇪Bad Nauheim, Germany
Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH
🇩🇪Essen, Germany
Klinik Johann Wolfgang von Goethe Uni
🇩🇪Frankfurt, Germany
Städtische Klinik Lüneburg
🇩🇪Lüneburg, Germany
Klinikum Ernst von Bergmann
🇩🇪Potsdam, Germany
Anticancer Hospital Ag. Savas
🇬🇷Athens, Greece
Alexandras General Hospital of Athens
🇬🇷Athens, Greece
University Hospital of Larissa
🇬🇷Larissa, Greece
Metropolitan Hospital
🇬🇷Piraeus, Greece
Euromedical General Clinic of Thessaloniki
🇬🇷Thessaloniki, Greece
Queen Mary Hospital
🇭🇰Hong Kong, Hong Kong
Pamela Youde Nethersole Eastern Hospital
🇭🇰Hong Kong, Hong Kong
Tuen Mun Hospital
🇭🇰Hong Kong, Hong Kong
Budapesti Szent Margit Korhaz
🇭🇺Budapest, Hungary
Orszagos Onkologiai Intezet
🇭🇺Budapest, Hungary
Debreceni Egyetem Klinikai Kozpont
🇭🇺Debrecen, Hungary
Max Super Speciality Hospital
🇮🇳North WEST Delhi, Delhi, India
Manipal Hospital
🇮🇳Bangalore, Karnataka, India
Tata Memorial Hospital
🇮🇳Mumbai, Maharashtra, India
TATA Medical Centre
🇮🇳Kolkata, WEST Bengal, India
AORN'S.G.Moscati
🇮🇹Avellino, Campania, Italy
Università degli Studi Federico II
🇮🇹Napoli, Campania, Italy
A.O. Universitaria Policlinico Di Modena
🇮🇹Modena, Emilia-Romagna, Italy
Asst Degli Spedali Civili Di Brescia
🇮🇹Brescia, Lombardia, Italy
Ospedale San Raffaele
🇮🇹Milano, Lombardia, Italy
Irccs Istituto Nazionale Dei Tumori (Int)
🇮🇹Milano, Lombardia, Italy
Azlenda Ospendaliero-Universitaria Pisana
🇮🇹Pisa, Toscana, Italy
Instituto Nacional De Cancerologia
🇲🇽Distrito Federal, Mexico CITY (federal District), Mexico
Bialostockie Centrum Onkologii
🇵🇱Bialystok, Poland
Uniwersyteckie Centrum Kliniczne
🇵🇱Gda?sk, Poland
Narodowy Instytut Onkologii Odzia? w Gliwicach
🇵🇱Gliwice, Poland
Wielkopolskie Centrum Onkologii
🇵🇱Poznan, Poland
Centrum Onkologii Instytut im.M. Sklodowskiej-Curie
🇵🇱Warszawa, Poland
Hospital CUF Tejo
🇵🇹Lisboa, Portugal
Hospital de Santa Maria
🇵🇹Lisboa, Portugal
Hospital Beatriz Angelo
🇵🇹Loures, Portugal
IPO do Porto
🇵🇹Porto, Portugal
Filantropia Clinical Hospital
🇷🇴Bucuresti, Romania
Amethyst Cluj
🇷🇴Cluj County, Romania
Cluj-Napoca Emergency Clinical County Hospital
🇷🇴Cluj-Napoca, Romania
Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj-Napoca
🇷🇴Cluj-Napoca, Romania
Republican Clinical Oncological Dispensary of the Ministry of Healthcare
🇷🇺Kazan, Karelija, Russian Federation
MEDSI Clinical Hospital on Pyatnitsky Highway
🇷🇺Moscow, Moskovskaja Oblast, Russian Federation
National Cancer Centre
🇸🇬Singapore, Singapore
Hospital General Universitario de Elche
🇪🇸Elche, Alicante, Spain
Hospital Universitari Germans Trias i Pujol
🇪🇸Badalona, Barcelona, Spain
Corporacio Sanitaria Parc Tauli
🇪🇸Sabadell, Barcelona, Spain
Hospital de Jerez de la Frontera
🇪🇸Jerez de La Frontera, Cadiz, Spain
Hospital Alvaro Cunqueiro
🇪🇸Vigo, Pontevedra, Spain
Hospital Universitario de Canarias
🇪🇸La Laguna, Tenerife, Spain
Hospital de Basurto
🇪🇸Bilbao, Vizcaya, Spain
Hospital Universitario Clínico San Cecilio
🇪🇸Granada, Spain
Hospital Juan Ramon Jimenez
🇪🇸Huelva, Spain
Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico
🇪🇸Jaen, Spain
Hospital General Universitario Gregorio Marañon
🇪🇸Madrid, Spain
Hospital Clinico San Carlos
🇪🇸Madrid, Spain
Hospital Quiron de Madrid
🇪🇸Madrid, Spain
Hospital Clinico Universitario Virgen de la Victoria
🇪🇸Malaga, Spain
Hospital Clinico Universitario de Salamanca
🇪🇸Salamanca, Spain
Hospital Universitario Virgen Macarena
🇪🇸Sevilla, Spain
Hospital Universitario Virgen del Rocio
🇪🇸Sevilla, Spain
Hospital Clínico Universitario de Valencia
🇪🇸Valencia, Spain
Hospital Universitario Miguel Servet
🇪🇸Zaragoza, Spain
Chia-Yi Christian Hospital
🇨🇳Chia-Yi, Taiwan
China Medical University Hospital
🇨🇳Taichung, Taiwan
National Cheng Kung Uni Hospital
🇨🇳Tainan, Taiwan
National Taiwan University Hospital
🇨🇳Taipei 100, Taiwan
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
Mackay Memorial Hospital
🇨🇳Taipei, Taiwan
Chulalongkorn Hospital
🇹🇭Bangkok, Thailand
Ramathibodi Hospital
🇹🇭Bangkok, Thailand
Srinagarind Hospital
🇹🇭Khon Kaen, Thailand
Songklanagarind Hospital
🇹🇭Songkla, Thailand
Adana Baskent University Hospital
🇹🇷Adana, Turkey
Antalya Training and Research Hospital
🇹🇷Antalya, Turkey
Ege University Medical Faculty
🇹🇷Bornova, ?zm?r, Turkey
Katip Celebi University Ataturk Training and Research Hospital
🇹🇷Izmir, Turkey
Inonu University Medical Faculty of Medicine
🇹🇷Malatya, Turkey
Medical Park Seyhan Hospital
🇹🇷Seyhan, Turkey
Ac?badem Altunizade Hastanesi
🇹🇷Üsküdar, Turkey
Barts & London School of Med
🇬🇧London, United Kingdom
Royal Cornwall Hospital
🇬🇧Truro, United Kingdom
Alabama Oncology
🇺🇸Birmingham, Alabama, United States
Roy and Patricia Disney Family Cancer Center- Providence Saint Joseph Medical Center
🇺🇸Buena, California, United States
UCLA Medical Center
🇺🇸Santa Monica, California, United States
Innovation Clinical Research Institute
🇺🇸Whittier, California, United States
Florida Cancer Specialists
🇺🇸West Palm Beach, Florida, United States
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
🇺🇸Carrollton, Georgia, United States
University of Iowa
🇺🇸Iowa City, Iowa, United States
New England Cancer Specialists
🇺🇸Scarborough, Maine, United States
The Valley Hospital
🇺🇸Paramus, New Jersey, United States
Levine Cancer Institute
🇺🇸Charlotte, North Carolina, United States
Abramson Cancer Center; Univ of Pennsylvania; Clinical Research Unit
🇺🇸Philadelphia, Pennsylvania, United States
Thompson Cancer Survival Center
🇺🇸Knoxville, Tennessee, United States
Mays Cancer Center at UT Health San Antonio MD Anderson Cancer
🇺🇸San Antonio, Texas, United States
Hematology Oncology Associates of Fredericksburg, Inc.
🇺🇸Fredericksburg, Virginia, United States
Virginia Oncology Associates - New Port News
🇺🇸Newport News, Virginia, United States
Virginia Oncology Associates
🇺🇸Norfolk, Virginia, United States
Virginia Cancer Institute
🇺🇸Richmond, Virginia, United States
Virginia Oncology Associates - Virginia Beach
🇺🇸Virginia Beach, Virginia, United States
Providence Regional Cancer Partnership
🇺🇸Everett, Washington, United States
Kadlec Clinic Hematology and Oncology
🇺🇸Kennewick, Washington, United States
Northwest Medical Specialties
🇺🇸Tacoma, Washington, United States
Macarthur Cancer Therapy Centre
🇦🇺Campbelltown, New South Wales, Australia
Cliniques Universitaires St-Luc
🇧🇪Bruxelles, Belgium
Jessa Zkh (Campus Virga Jesse)
🇧🇪Hasselt, Belgium
Clinique St. Elizabeth
🇧🇪Namur, Belgium
Hospital Sao Rafael - HSR
🇧🇷Salvador, Bahia, Brazil
Crio - Centro Regional Integrado de Oncologia
🇧🇷Fortaleza, Ceará, Brazil
Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
🇧🇷Ijui, Rio Grande Do Sul, Brazil
Santa Casa de Misericordia de Porto Alegre
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Hospital Sao Lucas - PUCRS
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Hospital Nossa Senhora da Conceicao
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL EAD
🇧🇬Sofia, Bulgaria
Sichuan Cancer Hospital
🇨🇳Chengdu City, China
West China Hospital - Sichuan University
🇨🇳Chengdu City, China
Chongqing Cancer Hospital
🇨🇳Chongqing, China
Sun Yat-sen Memorial Hospital
🇨🇳Guangzhou, China
The First Affilicated Hospital, Sun Yat-sen University
🇨🇳Guangzhou, China
Harbin Medical University Cancer Hospital
🇨🇳Harbin, China
First Affiliated Hospital of Medical College of Xi'an Jiaotong University
🇨🇳Xi'an, China
Zhejiang Cancer Hospital
🇨🇳Zhejiang, China
Henan Cancer Hospital
🇨🇳Zhengzhou, China
Institut Sainte Catherine
🇫🇷Avignon, France
CHRU Besançon
🇫🇷Besançon, France
Hospital de Base de Sao Jose do Rio Preto
🇧🇷Sao Jose do Rio Preto, São Paulo, Brazil
Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda
🇧🇷Sao Paulo, São Paulo, Brazil
Zhongshan Hospital Fudan University
🇨🇳Shanghai, China
Tianjin Medical University Cancer Institute & Hospital
🇨🇳Tianjing, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
🇨🇳Wuhan City, China
Polyclinique Bordeaux Nord Aquitaine
🇫🇷Bordeaux, France
Hopital Morvan
🇫🇷Brest, France
CLCC Leon Berard Lyon
🇫🇷Lyon, France
Groupe Hospitalier Diaconesses
🇫🇷Paris, France
Pole Regional De Cancerologie
🇫🇷Poitiers, France
Onkologische Schwerpunktpraxis Kurfürstendamm
🇩🇪Berlin, Germany
Gynäkologisches Zentrum Bonn
🇩🇪Bonn, Germany
Marienhospital Bottrop
🇩🇪Bottrop, Germany
Städtisches Klinikum Dessau
🇩🇪Dessau-Roßlau, Germany
Gynonco Düsseldorf, MVZ Medical Center GmbH
🇩🇪Düsseldorf, Germany
Frauenarztpraxis Dr. Apel, Dr. Kolpin
🇩🇪Erfurt, Germany
AGAPLESION Markus-Krankenhaus
🇩🇪Frankfurt, Germany
Praxis für Interdisziplinäre Onkologie und Hämatologie GbR
🇩🇪Freiburg, Germany
Diakovere Henriettenstift, Frauenklinik
🇩🇪Hannover, Germany
UNI-Klinikum Campus Kiel Klinik für Gynäkologie und Geburtshilfe
🇩🇪Kiel, Germany
Klinik & Poliklinik für Frauenheilkunde und Geburtshilfe, Campus Innenstadt
🇩🇪München, Germany
Leopoldina Krankenhaus der Stadt Schweinfurt GmbH
🇩🇪Schweinfurt, Germany
Gemeinschaftspraxis für Hämatologie und Onkologie Dr. Reichert/Dr.Janssen
🇩🇪Westerstede, Germany
Metropolitan General Hospital
🇬🇷Cholargos, Greece
University General Hospital of Heraklion
🇬🇷Crete, Greece
Rajiv Gandhi Cancer Institute & Research Center
🇮🇳New Delhi, Delhi, India
Hemato Oncology Clinic Ahmedabad Pvt Ltd
🇮🇳Ahmadabad, Gujarat, India
HCG Manavata Cancer Centre
🇮🇳Nashik, Maharashtra, India
Sahyadri Super Specialty Hospital Hadapsar
🇮🇳Pune, Maharashtra, India
Christian Med Clg & Hspt
🇮🇳Ratnagiri Kilminnal, Tamil NADU, India
U.O.C. Oncologia Medica Senologica
🇮🇹Napoli, Campania, Italy
Irccs Centro Di Riferimento Oncologico (CRO)
🇮🇹Aviano, Friuli-Venezia Giulia, Italy
Policlinico Universitario Agostino Gemelli
🇮🇹Roma, Lazio, Italy
Ospedale Civile - Livorno
🇮🇹Livorno, Toscana, Italy
International Cancer Institute (ICI)
🇰🇪Eldoret, Kenya
Aga Khan University Hospital
🇰🇪Nairobi, Kenya
Kyungpook National University Medical Center
🇰🇷Daegu, Korea, Republic of
National Cancer Center
🇰🇷Goyang-si, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Gangnam Severance Hospital
🇰🇷Seoul, Korea, Republic of
Seoul St Mary's Hospital
🇰🇷Seoul, Korea, Republic of
Korea University Guro Hospital
🇰🇷Seoul, Korea, Republic of
Investigacion Oncofarmaceutica
🇲🇽La Paz, BAJA California SUR, Mexico
Health Pharma Professional Research
🇲🇽Cdmx, Mexico CITY (federal District), Mexico
Centro Medico Dalinde
🇲🇽Cdmx, Mexico CITY (federal District), Mexico
Filios Alta Medicina
🇲🇽Monterrey, Nuevo LEON, Mexico
Centro de Investigacion Clinica de Oaxaca
🇲🇽Oaxaca de Juárez, Oaxaca, Mexico
Auckland City Hospital, Cancer and Blood Research
🇳🇿Auckland, New Zealand
Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii
🇵🇱Kraków, Poland
Centrul de Oncologie Sfantul Nectarie
🇷🇴Craiova, Romania
Oncomed SRL
🇷🇴Timisoara, Romania
FSBI Russian Oncology Research Center n.a. Blokhin of MOH RF
🇷🇺Moscow, Moskovskaja Oblast, Russian Federation
SBIH "Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM"
🇷🇺Moskva, Moskovskaja Oblast, Russian Federation
Nizhny Novgorod Regional Clinical Oncology Center
🇷🇺Nizhny Novgorod, Niznij Novgorod, Russian Federation
S-Pb clinical scientific practical center of specialized kinds of medical care (oncological)
🇷🇺Saint-Petersburg, Sankt Petersburg, Russian Federation
Medical Clinic "AB Medical group"
🇷🇺Sankt-peterburg, Sankt Petersburg, Russian Federation
SBI of Healthcare Leningrad Regional Oncology Dispensary
🇷🇺St PETERBURG, Sankt Petersburg, Russian Federation
FSBI?National Medical Research Center of Oncology named after N.N.Petrov? MHRF
🇷🇺St Petersburg, Sankt Petersburg, Russian Federation
SBIH Kaluga Region Clinical Oncology Dispensary
🇷🇺Kaluga, Russian Federation
LLC Medical and Sanitary Unit "Clinician"
🇷🇺Novosibirsk, Russian Federation
Regional Oncology Dispensary
🇷🇺Tomsk, Russian Federation
Regional Clinical Oncology Hospital
🇷🇺Yaroslavl, Russian Federation
Hacettepe University Medical Faculty
🇹🇷Ankara, Turkey
Ankara Bilkent City Hospital
🇹🇷Ankara, Turkey
Gazi University Medical Faculty, Oncology Hospital
🇹🇷Ankara, Turkey
Memorial Ankara Hastanesi
🇹🇷Ankara, Turkey
Dicle University Faculty of Medicine
🇹🇷Diyarbakir, Turkey
Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi
🇹🇷Edirne, Turkey
Istanbul Faculty of Medicine
🇹🇷Istanbul, Turkey
Istanbul University Cerrahpasa Faculty of Medicine
🇹🇷Istanbul, Turkey
Medeniyet University Goztepe Training and Research Hospital.
🇹🇷Istanbul, Turkey
Uganda Cancer Institute
🇺🇬Kampala, Uganda
Uzhgorod Central City Clinical Hospital
🇺🇦Uzhhorod, Katerynoslav Governorate, Ukraine
Municipal Noncommercial Institution Regional Center of Oncology
🇺🇦Kharkiv, Kharkiv Governorate, Ukraine
Municipal non profit enterprise of Sumy Regional Council Sumy Regional Clinical Oncology Disp
🇺🇦Sumy, Kholm Governorate, Ukraine
Innovacia Cancer Center
🇺🇦Liutizh, KIEV Governorate, Ukraine
CI Dnipropetrovsk CMCH #4 of Dnipropetrovsk RC SI Dnipropetrovsk MA of MOHU Ch of Oncology and MR
🇺🇦Dnipropetrovsk, Ukraine
Municipal Institution Kirovograd Regional Oncology Dispensary
🇺🇦Kirovograd, Ukraine
Kyiv City Clinical Oncological Center
🇺🇦Kyiv, Ukraine
Blackpool Victoria Hospital
🇬🇧Blackpool, United Kingdom
Royal Sussex County Hospital
🇬🇧Brighton, United Kingdom
Addenbrookes Hospital
🇬🇧Cambridge, United Kingdom
Cheltenham General Hospital
🇬🇧Cheltenham, United Kingdom
University College London Hospital
🇬🇧London, United Kingdom
Royal Free Hospital
🇬🇧London, United Kingdom
Royal Marsden Hospital - London
🇬🇧London, United Kingdom
Christie Hospital NHS Trust
🇬🇧Manchester, United Kingdom
Mount Vernon Cancer Centre
🇬🇧Northwood, United Kingdom
Royal Preston Hospital
🇬🇧Preston, United Kingdom
Royal Marsden Hospital - Surrey
🇬🇧Surrey, United Kingdom
Related News
Current and future immunotherapy for breast cancer | springermedizin.de
- Prev
- 1
- Next